Emergent BioSolutions posts Q3 2026 loss, cuts debt and updates 2026 revenue outlook
Emergent BioSolutions reported third‑quarter 2026 revenue of $110.0 million, a 52% year‑over‑year decline, and a net loss of $32.7 million versus a $51.2 million profit a year earlier. The CFO announced his retirement effective Dec. 31, 2026, and the company repurchased $75 million of senior unsecured notes. It also raised its full‑year 2026 revenue guidance to $600 million‑$645 million and lifted its adjusted gross‑margin outlook to 45%‑47%.
Why it matters
The loss and revenue miss could weigh on the stock, while the debt reduction and higher gross‑margin outlook improve the balance sheet and profitability outlook (the company said). The updated revenue range signals a lower top‑line expectation for 2026 (the company expects).
Key facts
- 1Q3 2026 total revenues were $110.0 million. stocktitan.net
- 2Q3 2026 net loss was $32.7 million, a net‑loss margin of 30%. stocktitan.net
- 3Adjusted net loss for Q3 2026 was $18.7 million. stocktitan.net
- 4Q3 2026 earnings per diluted share were -$0.64. investing.com
- 5Cash at quarter‑end was $176 million and total liquidity $226 million. finance.yahoo.com
- 6Gross debt at Sept. 30 was $514 million, down from $693 million a year earlier. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.